

Name Index

A

Addis, M. E., 40, 41
 Aesop, 1
 Aguilar, C., 171
 Ahn, H., 32, 40
 Albee, G., 21
 Alimohamed, S., 41
 Anastasi, A., 92
 Anderson, H., 122
 Anderson, T., 114
 Andrews, A. A., 87
 Angell, M., 154
 Anker, M., 93, 108, 109, 111
 Anthony, S. B., 18
 Antonuccio, D. O., 156, 168, 171
 Arcona, A., 156
 Arneill, A. B., 88
 Arnow, B., 162
 Arthus, N. M., 23
 Asarnow, J. R., 156
 Asay, T. P., 9, 33–35, 37, 38, 51, 63

B

Bachelor, A., 35, 36, 64, 65, 85,
 89, 193
 Badgett, R., 171
 Barber, J., 90, 92
 Barends, A. W., 90, 91
 Barley, D. E., 84
 Barondes, S., 166, 167
 Barrett, W., 120
 Barry, E., 148
 Bassman, R., 213, 217
 Beck, A., xviii
 Beckham, R., 173
 Belar, C., 7

Benson, K., 32, 40
 Berg, I. K., 58
 Bergin, A. E., 42, 93
 Bergstrom, D., 28
 Berman, J. S., 173, 174
 Berman, P., 2
 Berthelot, J., 4
 Beutler, L. E., 26, 27, 29, 41, 172
 Bevilacqua, L. J., 183
 Birmaher, B., 151, 156, 162
 Blaske, D., 43
 Blatt, S. J., 89
 Bohart, A., 34, 51, 198
 Boles, M., 148
 Bordin, E. S., 35, 64, 90
 Borduin, C., 43, 44
 Bornstein, R. F., 152, 171
 Borus, J., 24
 Bosely, S., 162
 Breggin, P., 158–162
 Brent, D. A., 151, 156
 Brickman, P., 121
 Brill, P. L., 83, 84, 108, 109
 Brown, E., 151
 Brown, G. S., 85
 Brown, J., 2, 14, 26, 32, 47, 83, 85, 86,
 88–90, 92–94, 96, 99, 117
 Browne, T., 1
 Burlingame, G. M., 86–88
 Burr, R., 49

C

Carlsson, A., 166, 167
 Carlson, G., 162
 Carroll, K. M., 36, 89
 Carroll, L., 32

Carson, R. C., 24
 Castonguay, L. G., 40
 Cervantes, M., 81
 Chalk, M., 14, 47, 94, 96, 117
 Chiquette, E., 171
 Ciotti, M., 5
 Clarke, G. N., 156
 Clarkin, J., 26, 27, 229
 Claud, D., 88, 89, 92, 93, 94
 Cleeland, C. S., 88
 Clement, P. W., 14
 Clouse, G. C., 86, 88
 Coates D., 121
 Cohen, D., 156, 161, 162
 Cohn, E., 121
 Coleman, S., 119
 Collins, J. F., 26, 32, 72
 Cone, L., 43
 Connors, G. J., 36, 89
 Conrad, J., 182
 Conte, H. R., 174
 Cornell, J. E., 5, 171
 Cross, H., 28
 Crowley, S. L., 156
 Cummings, N. A., 2, 5
 Curry, J. E., 156

D

Daley, D., 90, 92
 Dannon, P. N., 88
 Danton, W. G., 168
 Dardennes, R. M., 153
 Dattilio, F. M., 183
 Davies, M., 24
 de Shazer, S., 11, 56, 57, 96, 143
 DeBernardo, C., 28
 DeNelsky, G. Y., 168
 DeRubeis, R. J., 172
 Devlin, A. S., 88
 Dewey, J., 117
 DiClemente, C., 36, 89
 Dietrich, A., 5
 Diller, L. H., 148, 149
 Dobson, K., 40
 Docherty, J. P., 26, 32, 72
 Dolan, C., 173
 Dolberg, O. T., 88

Donovan D. M., 36, 89
 dosReis, S., 30, 148, 163
 Dreis, S., 2, 26, 32, 83, 85–86, 96,
 98, 117
 Duncan, B. L., 7, 9, 15, 19, 27, 28, 31–34,
 38, 47, 51, 52, 65, 71, 72, 78, 88–90,
 92–94, 96–99, 108–111, 114, 117,
 118, 121, 127, 128, 152, 183
 Dunner, D. L., 162
 Duriez, S., 1

E

Elkin, I., 26, 32, 36, 72, 89
 Emslie, G. J., 151–155, 161, 175
 Epston, D., 127
 Erickson, M. H., 10–12, 121, 125, 126
 Ernest, D. E., 151
 Eron, J., 127
 Eshun, S., 15
 Evan, C., 153

F

Fiester, S. J., 26, 32, 72
 Finch, A. E., 15
 First, M., 24
 Fisch, R., 121
 Fisher, R. L., 151, 162
 Fisher, S., 151–153, 162, 171–173
 Flexner, J. T., 13
 Fogel, B., 169
 Frank, A., 90, 92
 Frank, E., 174
 Frank, J. B., 121
 Frank, J. D., 29, 33, 121
 Freud, S., 7, 23, 37, 117, 187
 Fucci, B., 43

G

Garb, H. N., 24
 Gardner, J. F., 148
 Garfield, S., 26
 Garfinkel, R., 156
 Gaston, L., 71, 90
 Gelenberg, A. J., 162
 Geller, B., 162
 Georgaca, E., 187
 Ger, L. P., 88

256 NAME INDEX

Gergen, K. E., 179
 Gesten, E. L., 3
 Gibbon, M., 24
 Gilman, A. G., 168
 Gingerich, W., 56, 57, 96
 Glass, D. R., 26, 32, 72
 Goldfried, M. R., 40
 Goldman, A., 43
 Gollan, J., 40
 Goolishian, H., 122
 Gordon, J. S., 168
 Gortner, D., 40
 Grawe, K., 36
 Greenberg, L. S., 43, 90
 Greenberg, M. D., 152, 171
 Greenberg, R. P., 147, 152, 153, 168,
 170–173
 Greenhouse, J. B., 174
 Grochocinski, V., 174
 Grube, J., 28
 Grunhaus, L., 88

H

Haas, E., 83, 84
 Hagino, O. R., 162
 Hales, R., 169
 Haley, J., 127, 198
 Hansen, N. B., 83, 86, 88
 Hanych, J. M., 2
 Harding, C., 27
 Hardman, J. G., 168
 Hardy, R., 172
 Hargrave, G. E., 14
 Harper, D., 187
 Harwood, T. M., 41
 Hatcher, R. L., 90, 91
 Hatgis, C., 41
 Hawkins, E. J., 15, 83, 84, 95, 117
 Hayes, A. M., 40
 Healy, D., 29, 167, 169
 Heaton, K., 64
 Heiligenstein, J. H., 151
 Held, B. S., 121, 122
 Henggeler, S., 43
 Heracleitus, 56
 Hiatt, D., 14
 Hill, C. E., 64, 87, 108, 110

Hill, R. D., 83, 84
 Ho, S. T., 88
 Hoch, P., 120
 Hollon, S. D., 172
 Holloway, J. D., 29
 Hoog, S. L., 151
 Horvath, A. O., 35, 36, 65, 85, 89,
 90, 193
 Howard, K. I., 83–85, 108, 117,
 83, 109
 Howes, M., 24
 Hubble, M. A., 2, 7, 9, 12, 19, 27,
 28, 31, 33, 34, 38, 71, 72, 78, 79
 Hughes, C. W., 153
 Hunsley, J., 43
 Huxley, T. H., 21, 31

I

Iancu, I., 88
 Imber, S. D., 173

J

Jackson, G., 147
 Jacobson, J. G., 151
 Jacobson, N., 40
 Jaycox, L. H., 156
 Jensen, P. S., 148, 159
 John Paul, Pope, 77
 Johnson, L. D., 3, 15, 85, 89, 90,
 93, 117
 Johnson, S. M., 42, 43, 90–92

K

Kadera, S. W., 87
 Kane, J., 24
 Karasu, T. B., 174
 Karon, B., 198
 Karuza, J., 121
 Kaspar, 178
 Kaufman, J., 151
 Kaye, J., 179
 Kelledy, L., 119
 Keller, M. B., 162, 174
 Kelly, G., 120
 Kendell, R., 25
 Kennedy, J. F., 3
 Kesey, K., 181

Kidder, L., 121
 Kiesler, C., 4, 5
 Kinchin, K., 147
 Kipras, A., 156
 Kirk, S. A., 24, 25, 28–30, 187
 Kirsch, I., 168, 171, 172
 Klein, D. N., 162
 Klein, R. G., 162
 Kline, N., 165, 166
 Koerner, K., 40
 Koplewicz, H., 162
 Kopp, S. G., 119
 Kopte, S. M., 83, 84, 96, 117
 Kowatch, R. A., 153
 Krause, M. S., 83, 84,
 96, 117
 Kremer, T. G., 3
 Krupnick, J. L., 36, 89
 Kupfer, D. J., 174
 Kusumakar, V., 162
 Kutcher, S. P., 162
 Kutchins, H., 24, 25, 28–30, 187

L

Laird, N. M., 171
 Lambert, M. E., 42, 93
 Lambert, M. J., 9, 14, 15, 33–35, 37,
 38, 41, 51, 63, 83–88, 95, 96, 108,
 110, 117
 Lawrence, V., 171
 Lawson, D., 56, 96
 Leber, W. R., 26, 32, 72
 Lee, L., 82
 Lee, S., 171
 LeFever, G., 156, 159, 160
 Leighton, A. H., 171
 Leo, J., 156, 160
 Levitt, T., 81–83
 Lewisohn, P. M., 156
 Limbird, L. E., 168
 Lincoln, A., 12
 Longabaugh, R., 36, 89
 Luborsky, L., 32, 90, 92
 Lueger, R. J., 84
 Lund, T., 127
 Lurie, P., 155
 Luther, M., 171

Lutz, W., 83, 85, 108, 109
 Lynch, F., 148

M

Mackey, P., 156
 Madigan, S., 127
 Magder, L., 148
 Malik, M., 41
 Maling, M. S., 84
 Mann, B., 43
 Marcus, S. C., 148
 Markowitz, J. C., 162
 Martinovich, Z., 83–85,
 108, 109
 Masters, K., 86, 110
 Matt, G. E., 41
 McCafferty, J. P., 162
 McCall, R., 91
 McCullough, J. P., 162
 McGuire, W., 7
 McLaughlin, T., 187
 Melton, G., 43
 Messer, S., 37, 42
 Meyer, G., 50
 Michael, K. D., 156
 Mill, J. S., 145
 Miller, L., 28
 Miller, S. D., 2, 7, 9, 15, 19, 27, 28,
 31, 33, 34, 38, 47, 51, 58, 71, 72,
 78, 79, 88–90, 92–94, 96–98,
 117, 152, 183
 Mitka, M., 163
 Mohl, D. C., 185
 Moncrieff, J., 170, 172
 Mondin, G. W., 32, 40
 Monson, R. R., 171
 Moody, M., 32, 40
 Moore, T. J., 168, 172
 Moras, K., 83, 85, 108, 109
 Moreau, D., 156
 Morrell, B., 83, 84
 Morris, J., xviii
 Moyer, J., 36, 89
 Moynihan, D., 121
 Mufson, L., 156
 Mulrow, C. D., 171
 Murphy, J. J., 128

258 NAME INDEX

Murphy, J. M., 171
 Murphy, M., 28
 Musselman, D. L., 167
 Mustard, C., 4

N

Nace, D. K., 2, 26, 32, 83, 85–86, 96,
 98, 117
 Najavits, L., 90, 92
 Nathan K. I., 167, 168
 Nathan, P. E., 39
 Navarro, A. M., 41
 Neimeyer, R. A., 173, 174
 Nemeroff, C. B., 162, 167
 Nicholls, S. S., 172
 Nielsen, S. L., 15, 83, 84, 95, 117
 Nies, A., 168
 Nilsson, M., 151
 Noble, S., 41
 Noel, P. H., 171
 Norcross, J., 2, 119, 120
 Nutt-Williams, E., 64

O

Oakes, R., 162
 O'Connor, E., 159
 Ogles, B., 14, 41, 86, 96, 110
 Okiishi, J. C., 15
 Olfson, M., 148, 149
 Orlinsky, D. E., 36, 83, 84, 96, 117
 Orwell, G., 10, 44
 Osler, W., 164
 Ostrom, J., 50

P

Papatheodorou, G., 162
 Parker, I., 187
 Parks, B. K., 36
 Parloff, M. B., 9, 26, 32, 72
 Pascal, B., 126
 Pelham, W., 157–159
 Peller, J., 58, 127
 Phillips, G., 41
 Pilkonis, P. A., 26, 32, 36, 72, 89
 Plutchik, R., 174
 Polak, D., 88
 Pope, H., 24

Q

Quinlan, D. M., 89

R

Rabasca, L., 2
 Rabinowitz, V., 121
 Rall, T., 168
 Ramirez, G., 171
 Rao, S., 169
 Raue, P., 40
 Reynolds, L., 90, 92, 93
 Rhodes, R. H., 64
 Richardson, W. S., 171
 Riddle, M., 30, 148, 163
 Riley, W. T., 15
 Rintelmann, J., 40, 153
 Robinson, L. A., 173, 174
 Ronnestad, M. H., 36
 Rosenhan, D. L., 27
 Rosenzweig, S., 32, 33, 52
 Rossi, E. L., 121
 Rost, K., 5
 Rounsaville, B., 24
 Rush, A. J., 40, 153
 Rusk, G., 65, 79
 Russell, J. M., 162
 Ryan, N. D., 151, 162

S

Sack, W. H., 162
 Safer, S. J., 30, 148, 163
 Salovey, P., 27
 Saltzman, N., 120
 Sanchez, L., 3–5
 Sanderson, W. C., 15
 Sapirstein, G., 171, 172
 Sasich, L. D., 155
 Schappert, S., 5
 Schatzberg, A. F., 167
 Schiffer, R., 169
 Schindler, D., 43
 Scoboria, A., 168, 172
 Scott, J., 7
 Segal, L., 121
 Shadish, W. R., 41
 Shaha, S. H., 3, 85, 117
 Shapiro, D., 40

- Shea, M., 173
 Shea, T., 26, 32, 72
 Shelton, R. C., 172
 Shoemaker, W., 28
 Simmens, S., 36, 89
 Singer, B., 32
 Siobud-Dorocant, E., 153
 Siqueland, L., 90, 92
 Sluzki, C., 179
 Smart, D. W., 15, 83, 84,
 95, 117
 Smith, L., 43
 Snyder, S., 166
 Sobol, A. M., 171
 Soeken, K., 148
 Solovey, A., 65, 79
 Sorrell, R., 14, 47, 94,
 96, 117
 Sotsky, S. M., 89, 173
 Sparks, J. A., 11, 19, 88, 89, 92, 93, 94,
 97–99, 108, 110, 114, 118, 152,
 183, 200
 Spitzer, R., 24
 Stamm, K., 171
 Stich, F., 32, 40
 Stiles, W., 40
 Stowell-Smith, M., 187
 Strauss, D., 27
 Strober, M., 162
 Strosahl, K., 4
 Sun, W. Z., 88
 Swank, H., 22
 Sweeney, M., 162
 Symonds, B. D., 36
- T**
- Talbott, J., 169
 Talebi, H., 41
 Tallman, K., 34, 51, 198
 Taylor, P., 168
 Terranova, R. D., 2
 Thase, M. E., 162, 174
 Thompson, B., 64
 Tomiak, M., 4
 Tompson, M. C., 156
 Torrey, E., 120, 121
 Trivedi, M. H., 162, 171
- Truax, P., 40
 Turk, D., 27
 Turner, S., 3–5
- U**
- Umphress, V., 6, 88
- V**
- Valenstein, E., 169
 Vanderbos, G., 198
 Vandiver, W. D., 97
 Vermeersch, D. A., 15, 83, 84, 86–88,
 95, 117
 Vitiello, B., 161
- W**
- Wade, W. A., 41
 Wagner, K. D., 149, 151, 154, 162
 Walkup, J. T., 150, 160–163
 Walter, J., 58, 127
 Wampold, B. E., 9, 32, 34, 36–38, 40, 42,
 43, 47, 63
 Wang, M. S., 88
 Washington, G., 12–14
 Watkins, J. T., 26, 32, 36, 72, 89
 Watzlawick, P., 23, 121, 127
 Weakland, J., 121
 Weinberg, W. A., 40, 153
 Weiner-Davis, M., 56, 57, 96
 Weiss, B., 172
 Weissman, M. M., 148, 156
 Weller, E. B., 162
 Wessely, S., 172
 Whipple, J. L., 15, 83–84,
 95, 117
 Whitaker, R., 187, 198
 White, M., 127
 Wild, K. V., 174
 Wile, D., 121
 Wilford, J., 50
 Williams, J., 24
 Williams, J. W., Jr., 5, 171
 Williams, R., 43
 Williamson, D. E., 151
 Willutzki, U., 36
 Winters, N. C., 162

260 NAME INDEX

Wiser, S., 40
Wittchen, H., 24
Wolfe, B. E., 6
Wolfe, S. M., 155
Wong, E., 41
Woolston, J. L., 149

Y

Yanchar, S. C., 86, 88
Yudosky, S., 169

Z

Zablansky, A., 25
Zajecka, J., 162
Zanuck, D. F., 82
Zborowski, M. J., 171
Zeig, J. K., 10, 11
Zito, J. M., 30, 148, 163
Zubin, R., 27
Zuroff, D. C., 89
Zyzanski, S., 5

Subject Index

A

Acetylcholine, 166
 ADHD. *See* Attention deficit hyperactivity disorder (ADHD)
 Advil, 51
 Aesop, 1, 5
 Agency for Health Care Policy and Research, 171
 Agitation, 166
 Agoraphobia, 115–117
 AIDS, 66–68
 Alcoholism, 36
Alice's Adventures in Wonderland (Carroll), 32
 Allegiance, 37, 42, 43
 Alliance factors, 35–37
 Alliance monitoring, 64–65
 Alzheimer's Disease, 39
 American Association of Marriage and Family Therapy (AAMFT), 13, 149
 American Counseling Association (ACA), 13
 American Healthcare Institute, 6
American Journal of Psychiatry, 25
 American Psychiatric Association, 29, 39
 American Psychological Association (APA), 2, 6, 7, 13, 15, 23, 24, 33, 39, 83, 159, 214
American Psychologist, 84
 Amphetamine, 149. *See also* Medication
 Amy (client), 44, 45
Antidepressant Era, The (Healy), 29
 Antidepressants, 160, 164, 165, 170–175; and children, 151–152; and drug research, 152–156

Anxiety, 166
 Assessment, client-directed, outcome-informed therapy, 186–192
 Attention deficit hyperactivity disorder (ADHD), 149, 156, 157, 159, 160
 Attribution creep, 27, 28
 Axis II diagnosis, 29

B

Barbara (client), 112–113
 Beck Depression Inventory, 152
 Bible, 115
 Bill (client), 138
 Bioamine theories, 167–169
 Biochemical imbalance, 165–167
 Biogenic amine theory, 167
 Biological fundamentalism, 180
 Biological markers, 167–169
 Biomine theories, 167–169
 Bipolar disorder, 39
Blaming the Brain (Valenstein), 169
 Bloodletting, 10
 Bob (client), 126
 Borderline personality disorder (BPD), 8, 25, 30, 44
Boston Globe, 148
 Boulder conference, 21
 Bowen family therapy, 36, 37
Boys Don't Cry (cinema), 22
 BPD. *See* Borderline personality disorder (BPD)

C

California Psychotherapy Alliance Scales, 90
 Case writing, 192

- Catecholamine depletion, 166
 CBSC. *See* Change-by-session curve (CBSC)
 CBT. *See* Cognitive behavioral therapy (CBT)
 Celexa, 164
 Change, client's theory of, 19, 71–73; conversation, content, and change in, 122–124; learning and honoring, 73–75; and privileging client's voice, 126–145; and selection of content, 124–126; in tradition, 120–126; trusting, 145–146
 Change focus: and becoming change focused, 56–63; and expanding change into heroic stories, 58–63; and listening for change, 56–58
 Change-by-session curve (CBSC), 108–111
 Child Outcome Rating Scale (CORS), 224
 Child Session Rating Scale (CSRS), 225
 Chlorpromazine, 166, 167
 Cincinnati Bengals, 69
 Circular causality, 187–188
 Citalopram, 156
 Client: accepting goals of, 68–70; as agent of change, 34–35, 51; casting, in heroic roles, 51–55; *versus* clinician ratings, 152; as critic of therapy performance, 63–71; engagement in therapy process, 16; feedback, 15, 19; Kim, 125–126; language of, 73; Linda, 111; Mike, 75–78; Molly, 49; partnering with, 97–117; self-report, 14
 Client directed: becoming, 10–12, 49–80; *versus* theory driven, 19
 Client-directed, outcome-informed therapy: and assessment, 186–192; goals for therapy, 192–194; interventions of, 194–198; model for, 184–186
 Clients: Amy, 44; Barbara, 112–113; Bill, 138; Bob, 126; Emma, 201–211; Jan and Mark, 182–199; Joan, 59–63; Liz and Bob, 142–145; Maria, 16–18; Pat, 128–132; Robyn, 115–117; Sam, 65–68; Sarah, 69; Sean, 51; Stacy, 132–138; Steven, 113–115
 Clinical trials, 31, 32
 Clonidine, 148, 149. *See also* Medication
 Coassessment, 190, 191
 Cognitive behavioral therapy (CBT), 26, 32, 41, 44, 147
 Common cause, 39
 Common factors, 52; evolution and dangers of applying, 79–80
 Competency, 13; client, 52, 53, 133; and effectiveness, 13; orientation, 127, 138; *versus* outcome, 14
 Conflict avoidance pattern, 188, 189
 Content, 122–124; selecting, 124–126
 Continuing education requirement, 14
 Conversation, 122–124
- D**
- Deinonychus, 50
 Depression: adolescent, 156; biogenic amine theory of, 167; genetic, 127–132; major, 39; serotonin theory of, 168
 Destigmatization, 160–164
 Dexamethasone suppression test (DST), 167
Diagnostic and Statistical Manual of Mental Disorders (DSM), 22, 23, 25, 28, 29, 44, 118; *DSM-III*, 24; *DSM-IV*, 6, 9, 10, 18, 22
 Diagnostic classification, 21
 Diagnostic disorder, 23–28; and cultural bias, 29–30; as flawed extension of medical model, 30; and labeling, 27–28; and reliability, 24–25; and validity, 25–26
 Dialectical behavior therapy (DBT), 44
 Diathesis-stress paradigm, 130
 Disability, paradigm of, 198
 Disrupted homeostasis, 169
 Division of Clinical Psychology, 39
 Dodo bird verdict, 32, 33, 38, 42, 43, 51
 Dopamine, 166, 167
 Dose-effect relationship, 108

- “Dose-Effect Relationship in Psychotherapy” (*American Psychologist*), 84
- Drug companies, 29
- Drug Enforcement Administration, 148
- Drug research, four flaws of, 152–156
- DST. *See* Dexamethasone suppression test (DST)
- E**
- Eating disorders, 39
- Eclecticism, 119, 120
- Effectiveness: and competence, 13; Human Affairs International study of, 32; in medical health provider organizations, 13; proof of, 12; psychotherapy, 8; and Treatment of Depression Collaborative Research Project, 26
- Elavil, 152
- Eli Lilly and Company, 154, 155
- Emma (client), 201–211
- Emotionally focused therapy (EFT), 42–44
- “Emperor’s New Drugs” (Kirsch, Moore, Scoboria, and Nicholls), 172
- Epinephrine, 166
- ESPN, 70
- Ethical codes, 13
- Evaluation, 187
- Evidence-based practice, 3, 7, 21; and alliance factors, 35–37; and client factors, 34–35; and model or technical factors, 37–38; myth of, 31–47; reliability and validity of, 46–47; as ultimate silver bullet, 38–47
- Expectancy factors, 37
- Expertise, 190
- F**
- Family Counseling Office (Vestfold, Norway), 108
- Family Therapy Magazine*, 149
- FDA. *See* Federal Drug Administration (FDA)
- FDA Talk Paper* (FDA Press Office), 155, 162
- Federal Drug Administration (FDA), 150, 154, 155, 162, 172
- Federal Drug trials, 39
- First-session formula task, 143
- Fluoxetine (Prozac), 151, 152, 155, 156.
See also Medication
- French psychiatrists, 166
- From Placebo to Panacea* (Greenberg and Fisher), 156
- G**
- Genetic depression, 127–132
- Geodon, 161, 202
- GlaxoSmithKline, 162
- Global Assessment Scale, 152
- Goals, 192–194
- Godzilla*, 49, 50
- H**
- Hamilton Depression Scale, 152, 174
- Harding study, 27
- Harvard University, 81
- Hay Group, 3
- Heart and Soul of Change* (Hubble, Duncan, and Miller), 34
- Helping Alliance Questionnaire II (HAQ), 90, 92
- Heraclites, 56, 57
- Heroic stories: creating new, 56–63; expanding change into, 58–63; listening for, 52–55
- HIV, 67
- Hollywood, 82
- Homosexuality, 29
- Human Affairs International, 32
- I**
- Imipramine, 168
- IMS Health, 148, 149, 164
- India, 165
- Interpretation, 185
- Intervention, 194–198
- Interview, conversation *versus*, 122
- I-statement strategies, 195

- J**
 Jan and Mark (clients), 182–199
 Joan (client), 59–63
Journal of Consulting and Clinical Psychology, 6
- K**
 Killer D's, 35, 127
 Kim (client), 125–126
- L**
 Lilly. *See* Eli Lilly and Company
 Linda (client), 111, 112
 Linear causality, 187–188
 Linear regression, 110. *See also* Simple linear regression (SLR)
 Liz and Bob (clients), 142–145
- M**
 Magic pill, myth of, 9. *See* Medication
 Major depressive disorder (MDD), 155, 162
 Manuals, 41
 Maria (client), 16–18, 27, 53–55
 Massachusetts Medicaid program, 148
 MDD. *See* Major depressive disorder (MDD)
 Medicaid, 163
 Medical model, 7, 8, 10; diagnostic disorder as extension of, 30; myth of, 21–48; relational model *versus*, 19; script for, 180
 Medication: and antidepressants for children, 151–152; and bioamine theories, 167–169; and biochemical imbalance, 165–167; and demystifying magic pill, 170–173; and destigmatization, 160–164; and ethics of medicating children, 148–164; and medicated nation, 164–175; overview of, 147–148; *versus* therapy, 173–175
 Medicine and Healthcare Products Regulatory Agency (United Kingdom; MHRA), 162
 Mental disease, concept of, 21
 Mental health care benefits, 82
 Mental health practice: and client-directed, outcome-informed therapy assessment, 186–192; future of, 3–10; medical model applied to, 5, 6, 8; models and, 184–186; neurology of, 179–181; and paradigm of disability, 198–199; and pathology, 181–182; relational model for, 19; and responsibility, 199–200; state of, 1–3
 Mental health practitioners, 1, 2; ethical codes of, 13
 Mental Research Institute (MRI), 121, 127
Merriam-Webster's Collegiate Dictionary, 184, 195
 Methylphenidate (Ritalin), 148, 149. *See also* Medication
 Mike (client), 75–78
 Models, 37–38, 184–186
 Molly (client), 49, 63, 71, 79
 Montana, 50
 MRI. *See* Mental Research Institute (MRI)
 MTA Cooperative Group, 157, 158, 175
 Multimodal Treatment Study of Children with ADHD (MTA Cooperative Group), 157
 Multisystemic therapy (MST), 43, 44
- N**
 Narcotics Anonymous (NA), 65, 67
 National Action Agenda for Children's Mental Health (NAACMH), 163
 National Anxiety and Depression Awareness Day, 6
 National Association of Rights Protection and Advocacy, 213–214
 National Association of Social Workers (NASW), 11
 National Institute of Mental Health (NIMH), 22, 25, 26, 149, 161, 173
New England Journal of Medicine, 7, 154
 New Freedom Commission of Mental Health, 29

- New York Times*, 63
 Nicotine dependence, 39
 NIMH. *See* National Institute of Mental Health (NIMH)
 Norepinephrine, 166, 167
 Norway, 93, 108, 111
- O**
- One Flew Over the Cuckoo's Nest* (Kesey), 181
 Outcome: and future, 117–118;
 informed, becoming, 12–16;
 prediction of, 26; from process to,
 83–85; research, and Erickson's
 observations, 11, 12; successful,
 versus competent service, 19;
 tracking, 86–96
 Outcome management, 15
 Outcome Questionnaire 45.2 (OQ),
 86–88, 92, 94
 Outcome Rating Scale (ORS), 87–89,
 91, 110–113, 222; in action, 94–96;
 and checking for change, 102–107;
 and conversation, 124; and drug
 research, 156; experimental version
 of, for children, 224; experimental
 version of, for young children, 226;
 incorporating, in first meeting,
 99–100; introduction of, in first
 meeting, 98–99; reliability, validity,
 and feasibility of, 91–94
- P**
- Paroxetine, 156, 162
 Participation, client, 36, 182
 Pat (client), 128–132
 Pathology, 8, 29; and pathological
 labels, 15; swimming in, 181–182
 Paxil, 162, 164, 165
 Pedophilia, 138–142
 Peer ratings, 14
 Personal construct theory, 120
 Pharmaceutical marketing, 163–165
 Pittsburgh, Pennsylvania, 174
 Placebo, 151–156, 171, 172, 175
 Platelet-binding assays, 168
 Position, concept of, 121
 Pretreatment change, 56
 Problem focus, 189
 Project MATCH, 89
 Prozac (fluoxetine), 151–155, 161, 164,
 171, 175, 181. *See also* Medication
 Psychiatric diagnoses, myth of, 9,
 23–30; and diagnostic disorder,
 23–28
 Psychopharmacology, 166
 Psychosis, 166
Psychotherapy Bulletin, 213
 Psychotropic medications, 148, 149,
 160, 164. *See also* Medication
 Psychotherapy, and medical model, 5
- R**
- Randomized clinical trial (RCT), 22,
 39–41, 46
 RCI. *See* Reliable change index (RCI)
 RCT. *See* Randomized clinical
 trial (RCT)
 Relational bond, cementing, 64–65
 Relationship factors, 35–37
 Reliability, and diagnosis, 24–25
 Reliable change index (RCI), 110, 111
 Religious beliefs, 78, 115
 Reserpine, 165–168
 Risperdal, 148, 164
 Ritalin (methylphenidate), 148, 156, 216.
 See also Medication
 Robyn (client), 115–117
- S**
- Sam (client), 65–68
 Sarah (client), 69, 70
 Schizophrenia, 27, 28, 165–167, 201,
 202, 213, 214
Science, 27
 Sean (client), 51, 56
 Serotonin, 167, 168
 Seroxat (paroxetine), 162
 Session curve, change by, 108–110,
 109fig.4.2
 Session Rating Scale (SRS), 89–91, 223;
 in action, 94–96; and checking for
 change, 102–107; and conversation,
 124; experimental version of, for

266 SUBJECT INDEX

- Session Rating Scale (SRS) (*continued*)
 children, 225; experimental
 version of, for young children,
 227; incorporating, 101–102;
 introducing, 100–101; reliability,
 validity, and feasibility of, 91–94
- Session-by-session evaluation, 16
- Silver-bullet cure, myth of. *See*
 Evidence-based practice
- Simple linear regression (SLR),
 110–111; in action, 111–112
- SLR. *See* Simple linear regression (SLR)
- SSRIs, 148, 151, 152, 154–156,
 161, 162, 167, 168, 171. *See also*
 Medication
- Stacy (client), 132–138
- Star Trek* (science-fiction series), 5, 10
- Steven (client), 113–115
- Stimulants, 148, 149, 160; and children,
 156–160. *See also* Medication
- T**
- Talk therapy approach, 7
- Television, 82
- The Guardian*, 162
- Theory, formal *versus* informal, 121,
 122
- Theory-driven practice, client-directed
versus, 19
- Therapeutic alliance, 72fig.3.1
- Therapeutic relationship, 16
- Therapist allegiance, 122
- Therapy: consumer tips for, 219–212;
 client-directed, outcome-informed
 therapy's goals for, 192–194; drugs
versus, 173–175; factors arguing for
 change in, 33fig.2.1; from process to
 outcome in, 83–85; and randomized
 clinical trials, 41; tailoring tasks of,
 70–71
- Third-party payers, 15
- Treatment of Depression Collaborative
 Research Project (TDCRP), 26, 32,
 36, 42, 71, 72, 89
- Tricyclic antidepressants, 148, 151.
See also Medication
- Tylenol, 51
- U**
- University of Southern Mississippi, 213
- “Using the Outcome Rating Scale with
 Couples” (Anker and Duncan),
 109fig.4.2
- Utilization (Erickson), 121
- V**
- Validation, 65, 131
- Validity, in diagnosis, 25–26
- Valium, 180
- Vermont hospitals, 27
- W**
- Working Alliance Inventory (WAI),
 90, 94
- World Health Organization, 168
- World Series (1999), 165
- World War II, 21
- X**
- Xanax, 180
- Y**
- Yale University, 50
- Young Child Outcome Rating Scale
 (YCORS), 226
- Young Child Session Rating Scale
 (YCRS), 227
- Z**
- Zelmid (zimeclidine), 167
- Zoloft, 6, 7, 161, 164, 165, 170
- Zyprexa, 164